Singlepoint Healthcare Acquires Healix, Expanding National Infusion Capabilities

Singlepoint Healthcare has announced the acquisition of Healix, a prominent provider of outpatient infusion management services, for an undisclosed amount. The transaction, finalized on June 16, 2026, marks a significant step for Singlepoint as it seeks to enhance its national infusion services and capabilities, particularly in the management of patients with inflammatory diseases.

Healix, headquartered in Sugar Land, Texas, operates over 220 infusion centers across the United States, catering to physician-owned and ambulatory infusion centers. The company's extensive network allows it to deliver critical therapies in accessible outpatient settings, thereby improving patient care and outcomes. The acquisition is expected to bolster Singlepoint's existing healthcare platform, enabling the company to reduce care fragmentation and expedite access to advanced therapies for patients.

The strategic rationale behind this acquisition lies in the alignment of both companies' missions to provide integrated, patient-centered care. Singlepoint Healthcare, which focuses on delivering comprehensive care for individuals living with inflammatory diseases, aims to leverage Healix's established infrastructure and expertise in outpatient infusion management. This synergy is anticipated to enhance the quality of care provided to patients while expanding the range of services available to physician partners.

This acquisition is the third for Singlepoint in the past year, following its purchases of The Boster Center for Multiple Sclerosis and IV Solutions. These transactions reflect Singlepoint's aggressive growth strategy and commitment to building a robust multi-specialty network that addresses the needs of patients with complex health conditions. The integration of Healix's services is expected to further strengthen Singlepoint's position in the healthcare market, particularly in the specialty infusion sector.

Looking ahead, the acquisition of Healix could have broader implications for the healthcare landscape, particularly as the demand for outpatient infusion services continues to rise. With an increasing number of patients requiring specialized therapies, the consolidation of services may lead to improved efficiencies and better patient outcomes. As Singlepoint Healthcare continues to expand its capabilities, it is well-positioned to capitalize on the growing trend of integrated care models in the healthcare industry.